BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen to $357 from $380 and keeps an Outperform rating on the shares heading into the Q2 earnings. The firm is focused on updates to the company’s strategy for the commercial launch of Leqembi following the products full FDA approval, telling investors that it would like to hear more on how CEO Chris Viehbacher views the story for Biogen evolving following this critical approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Inches Closer to FDA Approval
- Biogen price target raised to $341 from $332 at RBC Capital
- Biogen shares little changed after resumption of trade
- Label for Biogen’s Leqembi not barrier to treatment, says William Blair
- Label for Biogen’s Leqembi generally as expected, says Mizuho